Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F076 - Late-breaking Research: Clinical Studies/Pediatric

Saturday, February 17; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe ground-breaking scientific developments in dermatologic research.
  • Evaluate and apply information from recent investigations to clinical practice.

Description

These forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed Forums.

Disclosures

  • Armstrong, April W., MD, MPH: AbbVie – C(H), SP(H); Boehringer Ingelheim – Data Safety Monitoring Board(H); Bristol-Myers Squibb – C(H); Celgene – I(Grants/Research Funding); Demira – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding), SP(H); Genzyme Corporation – C(H); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – SP(H); Janssen-Ortho Inc. – I(Grants/Research Funding); Leo Pharma Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Modernizing Medicine – C(H); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Ortho Dermatologics – C(H); Pfizer Inc. – C(H); Regeneron – I(NC); Regeneron Pharmaceuticals, Inc. – SP(H); Sanofi – I(NC), SP(H); Science 37, Inc. – C(H); UCB – I(Grants/Research Funding);
  • Dellavalle, Robert Paul, MD, PhD: Cochrane Collaboration – O(OB); Department. of Veterans Affairs – E(S), I(Grants/Research Funding); Journal of Investigative Dermatology – Independent Contractor(OB); Journal of the American Academy of Dermatology – O(OB); Pfizer Inc. – I(Grants/Research Funding); University of Colorado – E(S); UpToDate, Inc – Independent Contractor(IP);
  • Goldust Jouybari, Mohamad, MHS: no financial relationships exist with commercial interests.
  • Hebert, Adelaide A., MD: Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding), SP(H); Anacor Pharmaceuticals, Inc. – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Bayer – SP(H); Cassiopia – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chugai Pharma – I(Grants/Research Funding); Cutanea Life Sciences – A(H), I(Grants/Research Funding); Department of DEFENSE – O(Grants/Research Funding); Dermavant Sciences – I(Grants/Research Funding); Dermira – A(H), I(Grants/Research Funding); Encore Dermatology, Inc. – A(H); Galderma Laboratories, L.P. – A(H), SP(H); GlaxoSmithKline – A(H), Data Safety Monitoring Board(H), I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – SP(H); Mayne Pharma Group – I(Grants/Research Funding); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Menarini Group – SP(H); Menlo Therapeutics – A(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); NIH – I(Grants/Research Funding); Novan – I(H); Novartis Pharmaceuticals Corp. – O(H); Onset Therapeutics – SP(H); Ortho Dermatologics – A(H); Pfizer Inc. – Speaker/Faculty Education(H); Pharmaderm – A(H); PPD Inc. – I(Grants/Research Funding); Prim-Med – SP(H); Promius Pharma, LLC – A(H); Promius Pharmaceuticals – A(H), I(Grants/Research Funding); Regeneron – Data Safety Monitoring Board(H); Roivant Sciences – A(H); Shionogi USA – A(IP); Sienna Biopharmaceuticals – I(Grants/Research Funding); Sinclair Pharma – SP(H); Stiefel a GSK company – A(H); TopMD – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), SP(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding);
  • Hollingsworth, Parker: no financial relationships exist with commercial interests.
  • Kang, Sewon, MD: Dermira – SH(ST); Galderma Laboratories, L.P. – A(H); L'Oreal USA Inc. – C(H); Unilever Home & Personal Care USA – A(H);
  • Kelm, Ryan: no financial relationships exist with commercial interests.
  • Li, David: no financial relationships exist with commercial interests.
  • Lincoln, Vadim: no financial relationships exist with commercial interests.
  • Markova, Alina, MD: Incyte Corporation – I(Grants/Research Funding);
  • Paller, Amy S., MD: AbbVie – I(NC); Amgen – C(H), I(NC); Amicus Therapeutics – C(H); BridgeBio Pharma, LLC – A(H); Castle Creek Pharmaceuticals – C(H); Celgene Corporation – I(NC); Dermira – C(H); Eli Lilly and Company – C(H); Expanscience – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – C(H); Janssen Pharmaceuticals, Inc – I(NC); Leo Pharma Inc – I(Grants/Research Funding); Menlo Therapeutics – A(H); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H); Regeneron – C(H); Sanofi/Regeneron – A(H); Stiefel a GSK company – C(H); Valeant Pharmaceuticals North America LLC – C(H);
  • Tallman, Anna: E(S), SH(SO), SH(ST);
  • Tsao, Hensin, MD, PhD: Epiphany Dermatology – A(H); Massachusetts General Hospital – E(S); Relay Therapeutics – I(Grants/Research Funding);
Schedule
Saturday, February 17
3:30 PM
Lincoln / Gentamicin Therapy Induced Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa Patients Harboring Nonsense Mutations
3:42 PM
Tallman / Crisaborole Ointment Improves Disease Severity as Measured by the Atopic Dermatitis Severity Index (ADSI): Pooled Results From Two Phase 3 Studies
3:54 PM
Goldust Jouybari / Oral Ivermectin vs. Oral Fluralaner for the Treatment of Scabies
4:06 PM
Dr. Hebert / Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Pediatric Subgroup Analyses from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials
4:18 PM
Kelm / Pediatric Malignant Melanoma: A Report from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER)
4:30 PM
Hollingsworth / Global Skin Disease Burden: An Update from the Global Burden of Disease 2016 Study
4:42 PM
Dr. Armstrong / Online Care is Equivalent to In-person Care in Managing Psoriasis: A Multi-centered Randomized Controlled Trial
4:54 PM
Dr. Markova / Cytokines Associated with Progression to SCAR and Risk of Death in Hospitalized Cancer Patients with Morbilliform Rash
5:06 PM
Li / Prospective Evaluation of ALT-70 and Thermal Imaging for Diagnosing Lower Extremity Cellulitis
Event Details
  • Date
    Saturday, February 17
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 5B
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
Speakers
  • Adelaide A. Hebert, MD, FAAD
  • Alina Markova, MD, FAAD
  • Amy S. Paller, MD, FAAD
  • Anna Tallman
  • April W. Armstrong, MD, MPH, FAAD
  • David Li
  • Mohamad Goldust Jouybari, MHS
  • Parker Hollingsworth
  • Robert Paul Dellavalle, MD, PhD, FAAD
  • Ryan Kelm
  • Sewon Kang, MD, FAAD
  • Vadim Lincoln